MOTS-c — short for Mitochondrial Open reading frame of the 12S rRNA type-c — is one of the most intriguing molecules to emerge from mitochondrial biology in the last decade. Unlike most peptides in research catalogs, it is not encoded by the cell's nuclear DNA. Instead, MOTS-c is a small peptide encoded within a short open reading frame in the mitochondrial genome itself, placing it in a growing class of "mitochondrial-derived peptides" that appear to act as signaling molecules between the mitochondria and the rest of the cell.
First described by Lee and colleagues in 2015, MOTS-c drew immediate attention because the early work connected a tiny mitochondrial peptide to some of the most central levers of whole-body metabolism. This guide summarizes what the peer-reviewed literature reports about MOTS-c — and, just as importantly, where the human evidence is still limited.
For most of modern biology, the mitochondrion was treated mainly as the cell's power plant. The discovery of mitochondrial-derived peptides changed that picture: it suggested the mitochondrial genome can also produce short peptides that carry information outward, helping coordinate metabolism and the cell's response to stress. MOTS-c is the most studied member of this group alongside humanin. Because it is encoded in mitochondrial DNA and is thought to relay the metabolic state of the mitochondria to the nucleus, researchers often describe it as part of a "retrograde" signaling system — the mitochondria talking back to the cell.
The mechanism that made MOTS-c genuinely notable involves a well-known metabolic hub. In cell and animal studies, MOTS-c has been reported to act on the folate–methionine one-carbon cycle, leading to the accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMP analog. AICAR, in turn, is a recognized activator of AMP-activated protein kinase (AMPK) — often called the cell's "master energy sensor" because it switches on when energy is low and helps restore metabolic balance.
By engaging this AMPK pathway in laboratory models, MOTS-c has been associated with increased glucose uptake and shifts in cellular energy handling. It is worth stating the nuance plainly: this describes a mechanism observed in experimental systems, not a proven therapeutic effect in people. AMPK is a broad regulator, so a molecule that nudges it tends to touch many downstream processes at once rather than acting like a single-target drug.
The founding 2015 work reported that, in mice, MOTS-c influenced skeletal-muscle glucose metabolism and helped counter diet-induced obesity and insulin resistance. Animals on a high-fat diet showed metabolic improvements in these models, which the authors linked to the AMPK-dependent pathway described above. Later laboratory and animal studies extended the metabolic theme — for example, examining MOTS-c in the context of mitochondrial respiration in diabetic-heart models — reinforcing its role as a candidate metabolic regulator in preclinical research.
These are the observations that keep MOTS-c in the metabolic-research conversation. They are also, importantly, animal-model results. Effects seen in rodents on controlled diets do not automatically translate into humans, and the exposures used in laboratory studies are not the same thing as a validated human protocol.
MOTS-c is frequently described as an "exercise mimetic," and it is worth understanding exactly what that phrase means — and doesn't. In animal studies, the AMPK-linked signaling MOTS-c engages overlaps with some of the cellular changes that physical exercise also produces. Researchers have additionally reported that MOTS-c can translocate to the cell nucleus under metabolic stress, where it has been associated with regulation of stress-response and metabolic genes, and that its levels can rise with exercise. Together these findings led to the "exercise in a molecule" shorthand.
The responsible reading is narrower: MOTS-c shares mechanistic features with exercise physiology in laboratory systems. That is a description of overlapping cellular signaling, not evidence that a peptide reproduces the benefits of exercise in humans.
Another reason MOTS-c attracts interest is its connection to aging biology. Reviews of the literature note that circulating mitochondrial-derived peptides, including MOTS-c, tend to decline with age, and that mitochondrial dysfunction is a recognized hallmark of aging. Because MOTS-c sits at the intersection of mitochondrial signaling and AMPK-driven metabolism — two systems heavily implicated in healthspan research — it is studied as a probe for how mitochondrial signals may change across the lifespan. As with the metabolic work, this remains an area of active preclinical investigation rather than settled human science.
This is the part a responsible sourcing page should say plainly. The in-vitro and animal-model evidence for MOTS-c is real and growing, spanning the original mechanistic discovery, metabolic studies in mice, and follow-up work on mitochondrial function. The AMPK/AICAR mechanism in particular is grounded in well-understood metabolic biochemistry.
However, human clinical evidence for MOTS-c remains limited. In its 2026 review (see below), the FDA specifically noted an absence of human clinical studies supporting the proposed uses. A great deal of the enthusiasm around MOTS-c comes from mechanistic and preclinical work; confirming which of those effects translate to robust human outcomes — and at what exposures — is an open research question, not established fact. Treating rodent findings as proven human benefits is exactly the mistake this field is prone to, and we won't make it here.
MOTS-c was one of seven peptides evaluated at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting held July 23–24, 2026, which considered whether various nominated substances should be added to the 503A bulk drug substances list used in pharmacy compounding. MOTS-c had been nominated in connection with metabolic and bone-related uses. FDA reviewers highlighted the lack of human clinical data supporting the proposed uses, and MOTS-c does not have FDA-approved drug status or a compendial (USP/NF) monograph.
The practical takeaway for the research community is simple and unchanged: MOTS-c is not an approved drug. It is a research compound, and everything on this page describes laboratory and animal findings only.
For research applications, identity and purity are what separate a usable reference compound from an unknown. The MOTS-c we supply to the research community is a lyophilized powder with a third-party Certificate of Analysis (COA) available for each lot, strictly for in-vitro laboratory use:
New to handling lyophilized peptides? See our Research Center for storage, reconstitution and COA guidance.
MOTS-c (Mitochondrial Open reading frame of the 12S rRNA type-c) is a small mitochondrial-derived peptide encoded within the mitochondrial genome rather than the nuclear DNA. It was first described by Lee and colleagues in 2015 and is studied as a regulator of cellular metabolism and energy homeostasis.
In cell and animal studies, MOTS-c has been reported to influence the folate–methionine cycle, leading to accumulation of AICAR, an endogenous AMP analog that activates AMPK — a master regulator of cellular energy. Through this pathway researchers have observed effects on glucose uptake and metabolic regulation in laboratory models.
No. MOTS-c is not approved by the FDA for human or animal use. It was reviewed at the FDA Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 for possible inclusion on the 503A bulk drug substances list, where FDA reviewers noted an absence of human clinical studies supporting the proposed uses. MOTS-c sold for laboratory research is strictly for in-vitro and analytical use.
Because in animal studies its activation of AMPK-linked metabolic pathways resembles some of the cellular signaling changes associated with physical exercise. Researchers have also reported that MOTS-c levels can rise with exercise and that it can translocate to the nucleus under metabolic stress. This is a description of laboratory findings, not a demonstrated human outcome.